Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Miller
W H
WH
Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426-0989, USA. williamvhvmiller@sbphrd.com
Alberts
D P
DP
Bhatnagar
P K
PK
Bondinell
W E
WE
Callahan
J F
JF
Calvo
R R
RR
Cousins
R D
RD
Erhard
K F
KF
Heerding
D A
DA
Keenan
R M
RM
Kwon
C
C
Manley
P J
PJ
Newlander
K A
KA
Ross
S T
ST
Samanen
J M
JM
Uzinskas
I N
IN
Venslavsky
J W
JW
Yuan
C C
CC
Haltiwanger
R C
RC
Gowen
M
M
Hwang
S M
SM
James
I E
IE
Lark
M W
MW
Rieman
D J
DJ
Stroup
G B
GB
Azzarano
L M
LM
Salyers
K L
KL
Smith
B R
BR
Ward
K W
KW
Johanson
K O
KO
Huffman
W F
WF
D000818:Animals; D001552:Benzazepines / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology*; D001682:Biological Availability; D001862:Bone Resorption / Q000517:prevention & control; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D006207:Half-Life; D006801:Humans; D018716:Molecular Mimicry; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D011725:Pyridines / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism; D014018:Tissue Distribution
D001552:Benzazepines; D011725:Pyridines; D019030:Receptors, Vitronectin